CORRECTED-FDA studying deaths of two patients on Lilly's long-acting Zyprexa

(Corrects headline to FDA studying, rather than Lilly)

June 18 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it was investigating deaths of two patients who died following injections with Eli Lilly and Co's long-acting treatment for schizophrenia, called Zyprexa Relprevv.

The agency said the patients died 3 to 4 days after receiving an appropriate dose of the medicine.

(Reporting by Ransdell Pierson; Editing by Gerald E. McCormick)